A Single Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QLM3003 in Healthy Adult Chinese Subjects
Latest Information Update: 25 Sep 2023
At a glance
- Drugs QLM 3003 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 17 Sep 2023 Status changed from active, no longer recruiting to completed.
- 01 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2023 New trial record